Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial

IMPORTANCE: Single-agent carboplatin is often proposed instead of a conventional carboplatin–paclitaxel doublet in vulnerable older patients with ovarian cancer. Such an approach could have a detrimental effect on outcomes for these patients. OBJECTIVE: To compare the feasibility, efficacy, and safe...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:JAMA Oncol
Main Authors: Falandry, Claire, Rousseau, Frédérique, Mouret-Reynier, Marie-Ange, Tinquaut, Fabien, Lorusso, Domenica, Herrstedt, Jørn, Savoye, Aude-Marie, Stefani, Laetitia, Bourbouloux, Emmanuelle, Sverdlin, Robert, D’Hondt, Veronique, Lortholary, Alain, Brachet, Pierre-Emmanuel, Zannetti, Alain, Malaurie, Emmanuelle, Venat-Bouvet, Laurence, Trédan, Olivier, Mourey, Loïc, Pujade-Lauraine, Eric, Freyer, Gilles
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2021
Teme:
Original Investigation
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8063137/
https://ncbi.nlm.nih.gov/pubmed/33885718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2021.0696
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki